Liraglutide side effects and safety context

As a GLP-1 receptor agonist, liraglutide's side effect profile reflects its incretin activity and its effect on gastric emptying and appetite. Most effects described in the literature are gastrointestinal and are often most noticeable early, while the class also carries specific serious-risk warnings that guide how clinicians use it.

The most commonly reported effects are gastrointestinal, including nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reduced appetite. These tend to be most prominent early in use or when exposure increases, which is part of why the approved products use a gradual titration approach.

Product labeling for this class carries a boxed warning about thyroid C-cell tumors observed in rodent studies:

• The human relevance of the rodent finding is uncertain.
• The class is generally described as contraindicated with a personal or family history of medullary thyroid carcinoma.
• It is also cautioned against in multiple endocrine neoplasia syndrome type 2.

Pancreatitis and gallbladder-related events, including gallstones, are additional discussed concerns.

Additional themes include:

• Injection-site reactions.
• Increased heart rate discussed across the class.
• Higher hypoglycemia risk when combined with insulin or sulfonylureas.
• Extra uncertainty and quality risk with unregulated "research" sourcing.

Liraglutide's safety is characterized within regulated care, where contraindications, monitoring, and follow-up are defined. That framework does not transfer to unregulated vendor material, which is not the approved product. Any use should involve a prescribing clinician who can weigh individual risk factors, including thyroid, pancreatic, and gallbladder history.